MA31507B1 - Solutions pharmaceutiques orales contenant de la telbivudine - Google Patents

Solutions pharmaceutiques orales contenant de la telbivudine

Info

Publication number
MA31507B1
MA31507B1 MA32485A MA32485A MA31507B1 MA 31507 B1 MA31507 B1 MA 31507B1 MA 32485 A MA32485 A MA 32485A MA 32485 A MA32485 A MA 32485A MA 31507 B1 MA31507 B1 MA 31507B1
Authority
MA
Morocco
Prior art keywords
tilpifudine
oral medication
solutions contain
medication solutions
thymidine
Prior art date
Application number
MA32485A
Other languages
Arabic (ar)
English (en)
Inventor
Nabila Sekkat
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38724394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31507(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31507B1 publication Critical patent/MA31507B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur une solution pharmaceutique, appropriée pour une administration orale, qui comporte de la ß-l-thymidine/2'-désoxy-l-thymidine (telbivudine), un système de solvant approprié du point de vue pharmaceutique, un ou plusieurs agents exhausteurs de goût/de masquage du goût, un système de conservateur et un système de tampon approprié pour permettre à la fois la stabilité et la conservation de médicament.
MA32485A 2007-07-12 2010-01-07 Solutions pharmaceutiques orales contenant de la telbivudine MA31507B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07112381 2007-07-12
PCT/EP2008/059016 WO2009007426A1 (fr) 2007-07-12 2008-07-10 Solutions pharmaceutiques orales contenant de la telbivudine

Publications (1)

Publication Number Publication Date
MA31507B1 true MA31507B1 (fr) 2010-07-01

Family

ID=38724394

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32485A MA31507B1 (fr) 2007-07-12 2010-01-07 Solutions pharmaceutiques orales contenant de la telbivudine

Country Status (22)

Country Link
US (1) US8445457B2 (fr)
EP (1) EP2178503A1 (fr)
JP (1) JP5314014B2 (fr)
KR (3) KR20100029829A (fr)
CN (1) CN101686938B (fr)
AR (1) AR067630A1 (fr)
AU (1) AU2008274170B2 (fr)
BR (1) BRPI0815562A2 (fr)
CA (1) CA2693609A1 (fr)
CL (1) CL2008002025A1 (fr)
CO (1) CO6270204A2 (fr)
EC (1) ECSP109871A (fr)
IL (1) IL202961A (fr)
MA (1) MA31507B1 (fr)
MY (1) MY147366A (fr)
NZ (1) NZ582443A (fr)
PE (2) PE20130180A1 (fr)
RU (1) RU2493826C2 (fr)
TN (1) TN2010000008A1 (fr)
TW (1) TW200911302A (fr)
WO (1) WO2009007426A1 (fr)
ZA (1) ZA200908993B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55582B1 (sr) 2011-05-13 2017-06-30 Array Biopharma Inc Jedinjenja pirolidinil uree, pirolidinil tiouree i pirolidinil guanidina kao inhibitori trka kinaze
WO2014059363A1 (fr) * 2012-10-11 2014-04-17 Antrim Pharmaceuticals Llc Formulations de solution orale d'aripiprazole
NZ727418A (en) 2014-05-15 2023-03-31 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
EP3288562B1 (fr) * 2015-04-26 2022-03-16 MacKay Memorial Hospital Procédé pour améliorer la fonction rénale et/ou cardiaque chez des patients atteints de maladie rénale
CN107550866A (zh) * 2016-06-30 2018-01-09 康普药业股份有限公司 一种替比夫定制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856364A (en) 1991-03-01 1999-01-05 Warner Lambert Company Therapeutic antiviral-wound healing compositions and methods for preparing and using same
EP1023899A1 (fr) 1997-09-26 2000-08-02 Wakamoto Pharmaceutical Co., Ltd. Preparation aqueuse contenant un agent antiviral a ossature purine ou pyrimidine
DE19817265A1 (de) 1998-04-18 1999-10-21 Bayer Ag Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe
DE19817264A1 (de) 1998-04-18 1999-10-21 Bayer Ag Neue Dihydropyrimidine
AR037131A1 (es) * 2001-10-31 2004-10-20 Schering Corp Formulaciones de jarabe de ribavirina
TWI244393B (en) * 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
WO2006130217A2 (fr) 2005-04-01 2006-12-07 The Regents Of The University Of California Esters de phosphate de phosphonates de nucleosides substitues

Also Published As

Publication number Publication date
PE20130180A1 (es) 2013-03-06
CO6270204A2 (es) 2011-04-20
CN101686938B (zh) 2012-09-05
CL2008002025A1 (es) 2009-05-08
AU2008274170B2 (en) 2011-06-09
AR067630A1 (es) 2009-10-21
KR20100029829A (ko) 2010-03-17
MY147366A (en) 2012-11-30
EP2178503A1 (fr) 2010-04-28
CA2693609A1 (fr) 2009-01-15
CN101686938A (zh) 2010-03-31
ZA200908993B (en) 2010-09-29
PE20090476A1 (es) 2009-05-12
IL202961A (en) 2013-10-31
US8445457B2 (en) 2013-05-21
WO2009007426A1 (fr) 2009-01-15
JP2010533146A (ja) 2010-10-21
US20100197629A1 (en) 2010-08-05
JP5314014B2 (ja) 2013-10-16
TW200911302A (en) 2009-03-16
ECSP109871A (es) 2010-02-26
TN2010000008A1 (en) 2011-09-26
KR20140019040A (ko) 2014-02-13
RU2493826C2 (ru) 2013-09-27
RU2010104395A (ru) 2011-08-20
BRPI0815562A2 (pt) 2015-02-18
AU2008274170A1 (en) 2009-01-15
KR20120078754A (ko) 2012-07-10
NZ582443A (en) 2011-04-29

Similar Documents

Publication Publication Date Title
RU2470016C2 (ru) Производное бипиразола
AR033168A1 (es) Solucion oral de aripiprazol
MA31507B1 (fr) Solutions pharmaceutiques orales contenant de la telbivudine
CL2010000816A1 (es) Formulacion adecuada para administracion subcutanea que comprende al menos 100 mg/ml de ctlaig, un azucar, y un portador acuoso farmaceuticamente estable; articulo de fabricacion que comprende al menos un recipiente que contiene la formulacion antes mencionada. (divisional solicitud n° 3597-06)
UY27940A1 (es) Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a
MA28740B1 (fr) Methodes de traitement d'infections endobronchiques
AR038385A1 (es) Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo
EE200300295A (et) Kinuklidiinkarbamaadi derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette nähtud respiratoorsete, kuseelundite või mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon
HUP0102033A2 (hu) PEG IFN-alfa és ribavirin felhasználása krónikus hepatitis C kezelésére
ATE250924T1 (de) Cyklosporin, hyaluronsäure und polysorbate enthaltenes augenarzneimittel
EA200970469A1 (ru) Антитела-агонисты рецептора trkb и их применение
DK1526839T3 (da) Orale farmaceutiske former for flydende lægemidler med forbedret biotilgængelighed
BRPI0407583A (pt) solução oftálmica lìmpida e estável
ATE444061T1 (de) Transdermales therapeutisches system für parkinson-krankheit mit hohen rotigotin- plasmaspiegeln
EA200401227A1 (ru) Система доставки лекарства с контролируемым высвобождением, включающая правастатин
ATE505183T1 (de) Den geschmack verdeckende auslaufsichere formulierung
WO2001047913A3 (fr) Derives substitues d'acide n-benzyl-indol-3-yl-glyoxalique a action antitumorale
EE200200483A (et) Uus iseemulgeeruv ravimi manustamise süsteem
CL2009000980A1 (es) Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006).
BR0210650A (pt) Tablete, e, uso do mesmo
ATE311928T1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
WO2005044186A3 (fr) Formulations pharmaceutiques destinees a etre inhalees utilisant des agents dessechants et methodes d'administration desdites formulations pharmaceutiques
WO2007124700A3 (fr) Composition pharmaceutique contenant un dérivé de taxane, destinée à l'élaboration d'une solution pour perfusion, sa méthode d'élaboration et ses applications
WO2003020214A3 (fr) Composes derives des acides biliaires permettant d'ameliorer l'absorption orale et la biodisponibilite systemique de medicaments
MA27850A1 (fr) Preparations pharmaceutiques contenant de l'amoxicilline et du clavulanate